Cowen and Company set a $16.00 price target on Innoviva, Inc. (NASDAQ:INVA) in a research report released on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on INVA. Stifel Nicolaus reiterated a hold rating and issued a $15.00 price objective on shares of Innoviva in a report on Friday. Robert W. Baird reiterated a neutral rating and issued a $13.00 price objective (up from $11.00) on shares of Innoviva in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Innoviva from a sell rating to a hold rating in a report on Monday, July 17th. Finally, ValuEngine cut shares of Innoviva from a buy rating to a hold rating in a report on Friday, June 2nd. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Innoviva has an average rating of Buy and a consensus price target of $15.00.

Shares of Innoviva (NASDAQ INVA) opened at 13.72 on Friday. The firm has a 50-day moving average price of $12.82 and a 200-day moving average price of $12.33. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of 17.17 and a beta of 2.56. Innoviva has a one year low of $8.67 and a one year high of $14.55.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.02. The business had revenue of $58.60 million during the quarter, compared to analysts’ expectations of $50.53 million. Innoviva had a net margin of 52.56% and a negative return on equity of 27.37%. The business’s revenue was up 80.3% on a year-over-year basis. During the same period last year, the firm posted $0.13 earnings per share. Analysts anticipate that Innoviva will post $1.11 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/innoviva-inc-nasdaqinva-pt-set-at-16-00-by-cowen-and-company/1465897.html.

In related news, VP Theodore J. Jr. Witek sold 7,815 shares of the firm’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $12.01, for a total transaction of $93,858.15. Following the completion of the sale, the vice president now directly owns 251,968 shares in the company, valued at $3,026,135.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Old Mutual Global Investors UK Ltd. boosted its stake in shares of Innoviva by 160.6% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 183,998 shares of the biotechnology company’s stock worth $2,544,000 after buying an additional 113,388 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Innoviva during the first quarter valued at approximately $688,000. ARP Americas LLC purchased a new stake in shares of Innoviva during the first quarter valued at approximately $173,000. Acadian Asset Management LLC purchased a new stake in shares of Innoviva during the first quarter valued at approximately $2,061,000. Finally, Louisiana State Employees Retirement System increased its stake in shares of Innoviva by 1.9% in the first quarter. Louisiana State Employees Retirement System now owns 31,600 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 600 shares during the period. Hedge funds and other institutional investors own 74.99% of the company’s stock.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.